Home LiteratureArticle Details
PMID: 24091309 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner.

Molecular oncology ·Vol. 8 ·No. 1 ·2014-02-00 ·Pages 50-8

Põlajeva J, Bergström T, Edqvist PH, Lundequist A, Sjösten A, Nilsson G, Smits A, Bergqvist M, Pontén F, Westermark B, Pejler G, Forsberg Nilsson K, Tchougounova E

Abstract

Recently, glioma research has increased its focus on the diverse types of cells present in brain tumors. We observed previously that gliomas are associated with a profound accumulation of mast cells (MCs) and here we investigate the underlying mechanism. Gliomas express a plethora of chemoattractants. First, we demonstrated pronounced migration of human MCs toward conditioned medium from cultures of glioma cell lines. Subsequent cytokine array analyses of media from cells, cultured in either serum-containing or -free conditions, revealed a number of candidates which were secreted in high amounts in both cell lines. Among these, we then focused on macrophage migration inhibitory factor (MIF), which has been reported to be pro-inflammatory and -tumorigenic. Infiltration of MCs was attenuated by antibodies that neutralized MIF. Moreover, a positive correlation between the number of MCs and the level of MIF in a large cohort of human glioma tissue samples was observed. Further, both glioma-conditioned media and purified MIF promoted differential phosphorylation of a number of signaling molecules, including signal transducer and activator of transcription 5 (STAT5), in MCs. Inhibition of pSTAT5 signaling significantly attenuated the migration of MCs toward glioma cell-conditioned medium shown to contain MIF. In addition, analysis of tissue microarrays (TMAs) of high-grade gliomas revealed a direct correlation between the level of pSTAT5 in MCs and the level of MIF in the medium. In conclusion, these findings indicate the important influence of signaling cascades involving MIF and STAT5 on the recruitment of MCs to gliomas.

Keywords
BBB CBMC CF CI GBM Glioma IHC MC MIF Mast cell STAT TMA blood–brain barrier cord blood mast cell cytoplasmic fraction cytoplasmic intensity glioblastoma multiforme immunohistochemistry mast cell microphage migration inhibitory factor pSTAT5 signal transducer and activator of transcription tissue microarray
MeSH Terms
Brain/metabolism,pathology Brain Neoplasms/metabolism,pathology Cell Line, Tumor Cell Movement Glioma/metabolism,pathology Humans Macrophage Migration-Inhibitory Factors/metabolism Mast Cells/metabolism,pathology STAT5 Transcription Factor/metabolism
Chemicals
Macrophage Migration-Inhibitory Factors STAT5 Transcription Factor
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Põlajeva Jelena
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: jelena.polajeva@igp.uu.se.
Bergström Tobias
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: tobias.bergstrom@igp.uu.se.
Edqvist Per-Henrik
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: per-henrik.edqvist@igp.uu.se.
Lundequist Anders
Swedish University of Agricultural Sciences, Department of Anatomy, Physiology and Biochemistry, BMC, Box 575, SE-751 23 Uppsala, Sweden. Electronic address: lundequist@gmail.com.
Sjösten Anna
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden.
Nilsson Gunnar
Karolinska Institutet, Department of Medicine, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden. Electronic address: gunnar.p.nilsson@ki.se.
Smits Anja
Uppsala University Hospital, Department of Neuroscience, Neurology, SE-751 85 Uppsala, Sweden. Electronic address: anja.smits@neuro.uu.se.
Bergqvist Michael
Uppsala University Hospital, Department of Neuroscience, Neurology, SE-751 85 Uppsala, Sweden. Electronic address: michael.bergqvist@onkologi.uu.se.
Pontén Fredrik
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: fredrik.ponten@igp.uu.se.
Westermark Bengt
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: bengt.westermark@igp.uu.se.
Pejler Gunnar
Swedish University of Agricultural Sciences, Department of Anatomy, Physiology and Biochemistry, BMC, Box 575, SE-751 23 Uppsala, Sweden. Electronic address: gunnar.pejler@slu.se.
Forsberg Nilsson Karin
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: karin.nilsson@igp.uu.se.
Tchougounova Elena
Uppsala University, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. Electronic address: elena.chugunova@igp.uu.se.
References (30)
30 references, click to expand
  1. Constitutive Akt1 signals attenuate B-cell receptor signaling and proliferation, but enhance B-cell migration and effector function.
    Eur J Immunol. 2012 Dec;42(12):3381-93 PMID: 22930469
  2. Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12.
    PLoS One. 2011;6(9):e25222 PMID: 21949886
  3. Microglial action in glioma: a boon turns bane.
    Immunol Lett. 2010 Jun 15;131(1):3-9 PMID: 20338195
  4. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.
    Clin Cancer Res. 2010 Apr 15;16(8):2257-65 PMID: 20371681
  5. Towards a knowledge-based Human Protein Atlas.
    Nat Biotechnol. 2010 Dec;28(12):1248-50 PMID: 21139605
  6. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas.
    J Vis Exp. 2012 May 31;(63): PMID: 22688270
  7. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
    Br J Pharmacol. 2008 Aug;154(8):1572-82 PMID: 18500355
  8. New molecular targets in angiogenic vessels of glioblastoma tumours.
    Expert Rev Mol Med. 2008 Aug 07;10:e23 PMID: 18684337
  9. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma.
    Oncogene. 2009 Jun 11;28(23):2266-75 PMID: 19421151
  10. Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation.
    Pediatr Blood Cancer. 2008 Apr;50(4):812-7 PMID: 17914737
  11. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Oncogene. 2006 Aug 10;25(35):4913-22 PMID: 16547494
  12. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.
    Cancer Res. 2010 Jun 15;70(12):4829-39 PMID: 20501837
  13. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.
    Leuk Res. 2003 Aug;27(8):677-82 PMID: 12801524
  14. Inflammation and cancer: macrophage migration inhibitory factor (MIF)--the potential missing link.
    QJM. 2010 Nov;103(11):831-6 PMID: 20805118
  15. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors.
    Stem Cells. 2006 Apr;24(4):1030-41 PMID: 16253981
  16. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.
    J Neurooncol. 2012 Jan;106(1):43-51 PMID: 21725855
  17. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.
    Biochim Biophys Acta. 2009 Aug;1796(1):19-26 PMID: 19233249
  18. Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells.
    Int J Cancer. 2011 Jul 1;129(1):45-60 PMID: 20824710
  19. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.
    Nat Med. 2007 May;13(5):587-96 PMID: 17435771
  20. Accessories to the crime: functions of cells recruited to the tumor microenvironment.
    Cancer Cell. 2012 Mar 20;21(3):309-22 PMID: 22439926
  21. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner.
    Mol Oncol. 2014 Feb;8(1):50-8 PMID: 24091309
  22. Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme.
    Am J Pathol. 2003 Jan;162(1):11-7 PMID: 12507885
  23. Mechanisms of local immunoresistance in glioma.
    Neurosurg Clin N Am. 2010 Jan;21(1):17-29 PMID: 19944963
  24. PROX1 is a predictor of survival for gliomas WHO grade II.
    Br J Cancer. 2011 May 24;104(11):1747-54 PMID: 21559010
  25. Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis.
    Clin Exp Immunol. 2008 May;152(2):328-35 PMID: 18355352
  26. Macrophage migration inhibitory factor is up-regulated in human first-trimester placenta stimulated by soluble antigen of Toxoplasma gondii, resulting in increased monocyte adhesion on villous explants.
    Am J Pathol. 2008 Jan;172(1):50-8 PMID: 18165264
  27. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  28. Human mast cells express two leukotriene C(4) synthase isoenzymes and the CysLT(1) receptor.
    Biochim Biophys Acta. 2002 Jun 13;1583(1):53-62 PMID: 12069849
  29. Signaling determinants of glioma cell invasion.
    Adv Exp Med Biol. 2013;986:121-41 PMID: 22879067
  30. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
    Blood. 2011 Mar 24;117(12):3421-9 PMID: 21233313

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com